Abstract: A method for manufacturing a package structure includes providing a carrier board; providing at least one die having a top surface, a bottom surface, and a side surface on the carrier board; and forming a protective layer to cover at least a portion of the side surface of the die. The die includes a substrate, a semiconductor layer, a gate structure, a source structure and a drain structure, at least one dielectric layer, and at least one pad. The semiconductor layer is disposed on the substrate. The gate structure is disposed on the semiconductor layer. The source and the drain structures are disposed on opposite sides of the gate structure. The dielectric layer covers the gate, source, and drain structures. The pad is disposed on the dielectric layer and penetrates through the dielectric layer to electrically contact with the gate, source or drain structure.

Abstract: A method for relieving memory dysfunction using Puerariae Radix Extract is provided, including decocting Puerariae Radix in water, concentrating the extracted product thereof, and administrating an effective dose of the Puerariae Radix extract to a subject. Since the present invention merely uses Puerariae Radix as an ingredient, it belongs to a Chinese herbal medicine of single drug prescription. Further, with the same amount of Puerarin, Puerariae Radix Extract of the present invention provides a better neuroprotective effect in comparison with Puerarin, which indicates that the Puerariae Radix extract contains more active neurotrophic ingredients other than Puerarin. Therefore, Puerariae Radix extract is more promising potential therapeutic medicine than Puerarin for relieving the symptoms of anxiety and cognitive impairment.

Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.

Abstract: A Garcinia mangostana composition, a medication and a health food including the same for enhancing learning ability and memory of a patient with Alzheimer's disease are provided. The Garcinia mangostana composition includes G. mangostana and P. quinquefolius. The net weight ratio of the G. mangostana to the P. quinquefolius ranges from 4:1 to 1:16. A total of 4.5 to 35 mg of G. mangostana is per kilogram bodyweight applied, and 9 to 70 mg of P. quinquefolius per kilogram bodyweight is applied. The G. mangostana composition is capable of reducing the neuronal cell death and increasing the neurite length of the subjects with Alzheimer's disease, as well as improving the short term memory and the long term memory of the test subjects.

Abstract: A method for enhancing learning ability and memory of patients with Alzheimer's disease using mocetinostat is provided. The method includes administering an effective dose of mocetinostat into a subject in need. Based on the administration of mocetinostat, A? accumulation, Tau protein phosphorylation, and neuroinflammation can be reduced, and the level of synaptophysin and numbers of serotonergic neuron can be increased. Hence, the damage caused by the injection of oligomeric A?25-35 within hippocampal CA1 is relieved. The method may be a potential solution for relieving the symptoms of anxiety and cognitive impairment.

Abstract: A method for relieving memory dysfunction using Puerariae Radix Extract is provided, including decocting Puerariae Radix in water, concentrating the extracted product thereof, and administrating an effective dose of the Puerariae Radix extract to a subject. Since the present invention merely uses Puerariae Radix as an ingredient, it belongs to a Chinese herbal medicine of single drug prescription. Further, with the same amount of Puerarin, Puerariae Radix Extract of the present invention provides a better neuroprotective effect in comparison with Puerarin, which indicates that the Puerariae Radix extract contains more active neurotrophic ingredients other than Puerarin. Therefore, Puerariae Radix extract is more promising potential therapeutic medicine than Puerarin for relieving the symptoms of anxiety and cognitive impairment.

Abstract: A method for treating abnormal ?-amyloid mediated diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises an indolylquinoline derivative represented by the following formula 1:

Abstract: A method for treating a tau-associated disease is disclosed, which comprises the step of administering a pharmaceutical composition to a subject in need. Particularly, a method for treating Alzheimer's disease is disclosed, which comprises the step of administering a pharmaceutical composition to a subject in need.

Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.

Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. The two disclosed quinoline derivatives have the inhibition effect for GSK-3? kinase activity, so as the two disclosed quinoline derivatives have the ability for inhibiting tau hyperphosphorylation or reducing tau aggregation.

Abstract: A medical composition for inhibiting the growth of cancer stem cells is disclosed. The medical composition is prepared by mixing herbal medicines with water or alcohol, followed by heating and extraction to obtain a filtrate. One of the medical compositions according to the present invention includes: Coptis chinensis, Scutellaria baicalensis, Phellodendron amourense, Gardenia jasminoides, Radix Glycyrrhizae, and Atractylodes japonica.

Abstract: A Garcinia mangostana composition, a medication and a health food including the same for enhancing learning ability and memory of a patient with Alzheimer's disease are provided. The Garcinia mangostana composition includes G. mangostana and P. quinquefolius. The net weight ratio of the G. mangostana to the P. quinquefolius ranges from 4:1 to 1:16. A total of 4.5 to 35 mg of G. mangostana is per kilogram bodyweight applied, and 9 to 70 mg of P. quinquefolius per kilogram bodyweight is applied. The G. mangostana composition is capable of reducing the neuronal cell death and increasing the neurite length of the subjects with Alzheimer's disease, as well as improving the short term memory and the long term memory of the test subjects.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy.

Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.

Abstract: A method for treating abnormal ?-amyloid mediated diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises an indolylquinoline derivative represented by the following formula 1:

Abstract: A pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and an application thereof are disclosed. The pharmaceutical composition includes: a berberine compound; and a pharmaceutically acceptable carrier. The application is the use of the berberine compound in the manufacture of a medicament for the inhibition of cancer stem cell growth or carcinoma metastasis.

Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy.